89bio, Inc. (ETNB)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about 89bio, Inc. (ETNB)

Company Performance

Current Price

as of Oct 16, 2024

$8.61

P/E Ratio

N/A

Market Cap

$911.88M

Description

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Metrics

Overview

HQSan Francisco, CA
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerETNB
Price$8.61+7.36%

Trading Information

Market Cap$911.88M
Float93.70%
Average Daily Volume (1m)664,283
Average Daily Volume (3m)581,528
EPS-$1.97

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income-$47.97M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$53.42M

EV$295.61M
EV/RevenueN/A
P/EN/A
P/SN/A
P/B1.75

Documents

Factset Street Account

89bio, Inc. reports Q3 EPS ($0.45) vs FactSet ($0.53) [9 est, ($0.61)-(0.42)] ($8.01, 0.00) (2023-11-08T21:05:08Z)

89bio announces new positive long-term data from the ENLIVEN Phase 2B trial of Pegozafermin in patients with nonalcoholic steatohepatitis (Nash) ($7.92, 0.00) (2023-11-27T13:04:58Z)

89bio announces additional data from the ENLIVEN Phase 2B trial of pegozafermin in patients with compensated cirrhotic (F4) NASH at AASLD The Liver Meeting 2023 ($7.46, 0.00) (2023-11-12T17:28:20Z)

Factset

Factset Business Description